Literature DB >> 20195613

[Modeling in value-based medicine].

A S Neubauer1, C Hirneiss, A Kampik.   

Abstract

Modeling plays an important role in value-based medicine (VBM). It allows decision support by predicting potential clinical and economic consequences, frequently combining different sources of evidence. Based on relevant publications and examples focusing on ophthalmology the key economic modeling methods are explained and definitions are given. The most frequently applied model types are decision trees, Markov models, and discrete event simulation (DES) models. Model validation includes besides verifying internal validity comparison with other models (external validity) and ideally validation of its predictive properties. The existing uncertainty with any modeling should be clearly stated. This is true for economic modeling in VBM as well as when using disease risk models to support clinical decisions. In economic modeling uni- and multivariate sensitivity analyses are usually applied; the key concepts here are tornado plots and cost-effectiveness acceptability curves. Given the existing uncertainty, modeling helps to make better informed decisions than without this additional information.

Mesh:

Year:  2010        PMID: 20195613     DOI: 10.1007/s00347-009-2038-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  30 in total

1.  The evaluation of screening policies for diabetic retinopathy using simulation.

Authors:  R Davies; P Roderick; C Canning; S Brailsford
Journal:  Diabet Med       Date:  2002-09       Impact factor: 4.359

Review 2.  Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Authors:  Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed
Journal:  Value Health       Date:  2005 Sep-Oct       Impact factor: 5.725

3.  Decision-analytical modelling in health-care economic evaluations.

Authors:  Xin Sun; Thomas Faunce
Journal:  Eur J Health Econ       Date:  2007-10-18

4.  Budget impact analyses get some respect.

Authors:  Peter J Neumann
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

5.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

6.  A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy.

Authors:  Torsten Lundgaard Christensen; Peter Bo Poulsen; Stefan Holmstrom; John G Walt; Michele Vetrugno
Journal:  Curr Med Res Opin       Date:  2005-11       Impact factor: 2.580

7.  Falls and health status in elderly women following first eye cataract surgery: an economic evaluation conducted alongside a randomised controlled trial.

Authors:  Tracey H Sach; Alexander J E Foss; Richard M Gregson; Anwar Zaman; Francis Osborn; Tahir Masud; Rowan H Harwood
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

8.  Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Authors:  Alan F Cruess; Gergana Zlateva; Xiao Xu; Gisèle Soubrane; Daniel Pauleikhoff; Andrew Lotery; Jordi Mones; Ronald Buggage; Caroline Schaefer; Tyler Knight; Thomas F Goss
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Expected value of sample information calculations in medical decision modeling.

Authors:  A E Ades; G Lu; K Claxton
Journal:  Med Decis Making       Date:  2004 Mar-Apr       Impact factor: 2.583

10.  Probabilistic analysis and computationally expensive models: Necessary and required?

Authors:  Susan Griffin; Karl Claxton; Neil Hawkins; Mark Sculpher
Journal:  Value Health       Date:  2006 Jul-Aug       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.